Filing Flows › Northwest Biotherapeutics (NWBO) › Q2 2025
Northwest Biotherapeutics (NWBO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Northwest Biotherapeutics (NWBO) reported revenue of $131K for the second quarter 2025 (Q2 2025), -74% from a year earlier and -65% from the quarter before.
Northwest Biotherapeutics, Q2 2025: revenue $131K (-74% year over year), net loss $15.4M, operating cash flow −$6.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $131K | -65% | -74% |
| Operating profit | −$14.8M | — | — |
| Net earnings | −$15.4M | — | — |
| Operating cash flow | −$6.7M | — | — |
What changed
Revenue was $131K in Q2 2025, down 74% year over year and down 65% from the previous quarter.
Operating costs exceeded revenue by $14.8M, an operating margin of -11281.7%. Total costs fell 17% while revenue fell 74%. The quarter ended with a net loss of $15.4M, narrower than the previous quarter's $19.3M loss. Minority interests bore $22K of it: to shareholders the quarter was a loss of $15.4M.
Operating cash flow was −$6.7M. Non-cash charges added back $500K of depreciation and $364K of share-based compensation. Working capital and other items added $7.8M. Capital expenditures of $304K exceeded it, leaving free cash flow of −$7.0M.
Questions
What was Northwest Biotherapeutics' revenue in the second quarter 2025?
Northwest Biotherapeutics (NWBO) reported revenue of $131K for the second quarter 2025 (Q2 2025), -74% from a year earlier and -65% from the quarter before.